摘要:
The present invention relates to Streptomyces sp. producing tautomycetin which possesses an immunosuppressive or antibacterial activities, a process for preparing tautomycetin from the said microorganism, and an immunosuppressant or immunosuppressive pharmaceutical composition comprising tautomycetin as an active ingredient which suppresses interleukin-2 production, CD69 and interleukin-2 receptor(IL-2R) expression on the cell surface, and graft rejection in the organ transplantation. The present inventors isolated a soil microorganism which produces a substance possessing antibiotic and immunosuppressive activities, and identified the said microorganism and substance as a novel Streptomyces sp. and tautomycetin, respectively. Further, the present inventors developed a method of manufacturing the tautomycetin in a large scale from the culture of the said microorganism and discovered that tautomycetin suppresses mouse mixed lymphocyte reaction(MLR) and the expression of IL-2 based on a series of experiments employing cell line transfected with a recombinant gene.
摘要:
The present invention relates to novel aminooligosaccharide derivative and pharmaceutically acceptable non-toxic salts thereof, which possess potent saccharide hydrolase inhibition and antibacterial activities. The invention also relates to a process for preparing the same and to pharmaceutical compositions containing the same as active ingredients. In accordance with the present invention, the inventors isolated novel aminooligosaccharide derivative from a soil microorganism categorized as Streptomyces sp., and discovered that it can be applied as potent inhibitors for saccharide hydrolases and antibacterial agents as well.
摘要:
The present invention relates a novel method of preparing an intermediate which is useful for synthesizing an antiulcerant. The present invention provides a method of preparing an intermediate of an antiulcerant which can obtain a high purity compound in high yield, with reduced production cost/time as compared to a conventional method.
摘要:
Compounds useful as angiogenesis inhibiting agents and processes for their preparation are disclosed. In one embodiment, the compounds of the invention are represented by Formula 1: ##STR1## Also disclosed is a pharmaceutical composition for inhibiting angiogenesis in a mammal, said composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof, as an active ingredient.
摘要:
According to example embodiments, an electrochromic device includes pixel containing a first sub-pixel and a second sub-pixel. The first sub-pixel includes a first electrolyte contacting a first electrochromic layer. The first electrochromic layer includes a first electrochromic material configured to display each one of transparency and at least two colors, based on a voltage applied to the first electrochromic material. The second sub-pixel includes a second electrolyte contacting a second electrochromic layer. The second electrochromic layer includes a second electrochromic material configured to display each one of transparency, black, and at least one color other than black, based on a voltage applied to the second electrochromic material.
摘要:
A polymerized toner is provided. The polymerized toner comprises a reactive anionic surfactant having at least one reactive functional group. The reactive anionic surfactant is added simultaneously with a dispersant to prepare an aqueous dispersion or is added within 2 hour after a polymerization reaction of a monomer mixture is initiated in an aqueous dispersion. This simultaneous or rapid addition allows the reactive anionic surfactant to be dispersed on the surface of the toner particles. The reactive anionic surfactant is located over the entire surface of the toner particles to increase the surface charge density of the toner, achieving good charge stability and excellent imaging characteristics.
摘要:
There is provided a method for manufacturing a toner capable of providing a toner having excellent low-temperature fixing property and anti-offset property by adjusting a molecular weight distribution of a polymerization toner to a narrow distribution range. The method is characterized in that a toner is polymerized using a reversible addition-fragmentation chain transfer polymerization (RAFT) method by adding a dithioacetate, xanthate or dithioester-based chain transfer agent in the polymerization of a toner. The method for manufacturing a toner comprises: dissolving a dispersant in water to prepare an aqueous dispersion solution; mixing a binder resin monomer, a charge control agent, a pigment, a wax and a dithioacetate, xanthate or dithioester-based chain transfer agent to prepare a monomer mixture; adding the monomer mixture to the aqueous dispersion solution and suspension-polymerizing the monomer mixture to form a toner composition; removing the dispersant from the toner composition; and drying the dispersant-free toner composition under a vacuum condition.
摘要:
Photoresist polymers and photoresist compositions are disclosed. A photoresist polymer represented by Formula 1 and a photoresist composition containing the same have excellent etching resistance, thermal resistance and adhesive property, and high affinity to an developing solution, thereby improving LER (line edge roughness). wherein X1, X2, X3, R1, R2, R3, R4, R5, m, n, o, a, b, c, d and e are as defined in the description.
摘要:
According to the present invention, provided are novel nucleoside derivatives having antiviral activity, in particular, anti-HBV (anti-Hepatitis-B Virus) activity, represented by general formula (I), wherein R.sub.1 represents hydrogen, phosphate, phosphonate, alkyl or acyl; R.sub.2 represents alkoxy or halogen; R.sub.3 represents substituted or non-substituted pyrimidine or purine base; and X represents O, S, SO or SO.sub.2 ; pharmaceutically acceptable salts thereof, and processes thereof. As the compound (I) has two or more asymmetric carbon atoms, all possible stereoisomers and mixtures thereof are included in the scope of the present invention. ##STR1##
摘要:
Nucleoside derivatives represented by formula (I); ##STR1## wherein, R.sub.1 represents hydrogen, phosphate or phosphonate group, R.sub.2 represents substituted or unsubstituted pyrimidine or purine base, and Z represents S, SO, SO.sub.2, O or C; or pharmaceutically acceptable salts thereof. Compound (I) can be obtained by reacting a compound of the formula (II); ##STR2## wherein, R.sub.7 represents hydrogen or hydroxy-protecting group, L represents aromatic or nonaromatic acyl, halide or alkoxy, and Z represents S, SO, SO.sub.2, O or C, with a base.